iHuman Inc.(IH)Earnings, Financials & Key RatiosiHuman Inc. (IH) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2025Q2
the company's inability to reverse a 6.9% year-over-year revenue decline suggests that its $605.1 million cash pile is currently being underutilized, offering little upside for growth-focused investors.
iHuman Inc. (IH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
iHuman Inc. (IH) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 29, 2026 | $0.06 | $29M |
| Q2 2026 | Mar 16, 2026 | $0.04 | $27M |
| Q4 2025 | Dec 29, 2025 | $0.06 | $29Mvs $29M+0.0% |
| Q4 2025 | Sep 18, 2025 | $0.08 | $28Mvs $28M+0.1% |
Recent stock market news and headlines for iHuman Inc. (IH)
BEIJING, June 29, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered knowledge and personal growth products, today announced its unaudited financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Revenues were RMB182.5 million (US$26.5 million), compared with RMB210.4 million in the same period last year.
New late-breaking data presentations underscore Jazz's significant progress in advancing holistic understanding of narcolepsy and idiopathic hypersomnia, including novel real-world evidence of meaningful changes in cardiometabolic risk markers following Xywav initiation For U.S. media and investors only DUBLIN, June 16, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH). These late-breaking presentations advance scientific understanding of individualized dosing regimens and the broader cardiometabolic impacts of reduced sodium exposure in patients living with these debilitating conditions.
Key metrics vs top competitors for iHuman Inc. (IH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.41 | $14.39M | 1.09 | -12.49% | 11.82% | 9.75% | 37.21% | |
| $1.76 | $638.43M | -14.23 | 34.99% | -5.26% | -20.84% | — | |
| $16.15 | $1.61M | -0.09 | 89.09% | -16.46% | — | — | |
| $10.00 | $1.87B | 3.62 | 34.21% | 13.82% | 10.85% | — | |
| $47.81 | $7.64B | 20.79 | 13.6% | 7.37% | 9.09% | — | |
| $13.05 | $1.54B | 98.51 | 5.03% | 1.82% | — | — |
iHuman Inc. (IH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when IH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
iHuman Inc. (IH) stock FAQ — growth, dividends, profitability & financials explained
iHuman Inc. (IH) reported $882.7M in revenue for fiscal year 2025. This represents a 569% increase from $131.9M in 2018.
iHuman Inc. (IH) saw revenue decline by 12.5% over the past year.
Yes, iHuman Inc. (IH) is profitable, generating $110.0M in net income for fiscal year 2025 (11.8% net margin).
Yes, iHuman Inc. (IH) pays a dividend with a yield of 37.21%. This makes it attractive for income-focused investors.
iHuman Inc. (IH) has a return on equity (ROE) of 9.8%. This is below average, suggesting room for improvement.
iHuman Inc. (IH) generated $45.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
